- Geron (NASDAQ:GERN -3%) is up 3.1% in after-hours trading following an in-line loss for its fourth quarter earnings on $220K in revenue.
- In the full year, the company eked out a profit of $46,000 vs. 2014's net loss of $35.7M. Revenues came to $36.4M, including full recognition of a $35M upfront payment from Janssen received in December 2014.
- Geron said the FDA granted orphan drug designation to imetelstat for the treatment of MF and for the treatment of MDS, and that the European Medicine Agency granted orphan drug designation to imetelstat for the treatment of MF.
- R&D expenses for 2015 were $17.8M vs. the prior year's $20.7M, mainly due to organizational resizing and lower costs to make imetelstat. G&A costs were $17.8M.
- Press Release